Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases
Aim: Therapeutic targeting of BRAF alterations in primary brain tumor patients has demonstrated clinical activity in case reports and early trials; however, there is limited high-level evidence of the efficacy. Patients & results: Targeting BRAF V600E mutations with concurrent dabrafenib and tra...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-12-01
|
Series: | CNS Oncology |
Subjects: | |
Online Access: | https://www.futuremedicine.com/doi/10.2217/cns-2019-0018 |